J
Jonathan M. Pitt
Researcher at Institut Gustave Roussy
Publications - 23
Citations - 6065
Jonathan M. Pitt is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 18, co-authored 23 publications receiving 4184 citations. Previous affiliations of Jonathan M. Pitt include Paris Descartes University & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou,Marie Vétizou,Marie Vétizou,Jonathan M. Pitt,Jonathan M. Pitt,Jonathan M. Pitt,Romain Daillère,Romain Daillère,Romain Daillère,Patricia Lepage,Nadine Waldschmitt,Caroline Flament,Caroline Flament,Sylvie Rusakiewicz,Sylvie Rusakiewicz,Bertrand Routy,Maria Paula Roberti,Maria Paula Roberti,Connie P.M. Duong,Connie P.M. Duong,Vichnou Poirier-Colame,Vichnou Poirier-Colame,Antoine Roux,Antoine Roux,Antoine Roux,Sonia Becharef,Sonia Becharef,Silvia C. Formenti,Encouse B. Golden,Sascha Cording,Gérard Eberl,Andreas Schlitzer,Florent Ginhoux,Sridhar Mani,Takahiro Yamazaki,Takahiro Yamazaki,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,David Enot,David Enot,Marion Bérard,Jérôme Nigou,Jérôme Nigou,Paule Opolon,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Paul Louis Woerther,Elisabeth Chachaty,Nathalie Chaput,Nathalie Chaput,Caroline Robert,Caroline Robert,Christina Mateus,Guido Kroemer,Didier Raoult,Ivo G. Boneca,Ivo G. Boneca,Franck Carbonnel,Mathias Chamaillard,Laurence Zitvogel +60 more
TL;DR: A key role is revealed for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade, which is found to depend on distinct Bacteroides species in mice and patients.
Journal ArticleDOI
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt,Marie Vétizou,Marie Vétizou,Marie Vétizou,Romain Daillère,Romain Daillère,Romain Daillère,Maria Paula Roberti,Takahiro Yamazaki,Takahiro Yamazaki,Bertrand Routy,Bertrand Routy,Bertrand Routy,Patricia Lepage,Ivo G. Boneca,Mathias Chamaillard,Guido Kroemer,Laurence Zitvogel +17 more
TL;DR: How a range of cancer-cell-autonomous cues, tumor-microenvironmental factors, and host-related influences might account for the heterogeneous responses and failures often encountered during therapies using immune-checkpoint blockade is reviewed.
Journal ArticleDOI
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
Jonathan M. Pitt,Aurélien Marabelle,Aurélien Marabelle,Alexander M.M. Eggermont,J-C. Soria,Guido Kroemer,Laurence Zitvogel +6 more
TL;DR: The composition of the TME is reviewed, how this attenuates immunosurveillance, and existing and potential strategies aimed at targeting cellular and molecular TME components are discussed.
Journal ArticleDOI
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
Benjamin Besse,Melinda Charrier,Valérie Lapierre,Eric Dansin,Olivier Lantz,David Planchard,Thierry Le Chevalier,Alain Livartoski,Fabrice Barlesi,Agnès Laplanche,Stéphanie Ploix,Nadege Vimond,Isabelle Peguillet,Clotilde Théry,Ludovic Lacroix,Inka Zoernig,Kavita M. Dhodapkar,Madhav V. Dhodapkar,Sophie Viaud,Jean-Charles Soria,Katrin S. Reiners,Elke Pogge von Strandmann,Frédéric Vély,Sylvie Rusakiewicz,Alexander M.M. Eggermont,Jonathan M. Pitt,Laurence Zitvogel,Nathalie Chaput +27 more
TL;DR: This phase II trial confirmed the capacity of Dex to boost the NK cell arm of antitumor immunity in patients with advanced NSCLC.
Journal ArticleDOI
Dendritic cell-derived exosomes for cancer therapy
Jonathan M. Pitt,Jonathan M. Pitt,Fabrice Andre,Fabrice Andre,Sebastian Amigorena,Jean-Charles Soria,Alexander M.M. Eggermont,Guido Kroemer,Laurence Zitvogel +8 more
TL;DR: This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer.